Constellation Pharmaceuticals (CNST) Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Constellation Pharmaceuticals (CNST) Prices 6.5M Share Common Offering at $34.50/Sh
December 11, 2019 5:57 AM ESTConstellation Pharmaceuticals, Inc., (NASDAQ: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has priced an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $34.50 per share,... More
Constellation Pharmaceuticals (CNST) PT Raised to $55 at Oppenheimer
December 9, 2019 4:21 PM ESTOppenheimer analyst Silvan Tuerkcan raised the price target on Constellation Pharmaceuticals (NASDAQ: CNST) to $55.00 (from $40.00) while maintaining a Outperform rating.
The analyst comments "CNST updated CPI-0610 data with efficacy stable in the key first-line (1L) population (n=15) and excellent tolerability in all settings. SVR35... More
